Fluorodopa f 18
Fluorodopa F (fluorodopa f 18) is a small molecule pharmaceutical. Fluorodopa f 18 was first approved as Fluorodopa f18 on 2019-10-10.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fluorodopa | New Drug Application | 2021-01-15 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
FLUORODOPA F-18, FLUORODOPA F18, FEINSTEIN | |||
| 2024-10-10 | NCE, W | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
85 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioma | D005910 | EFO_0000520 | — | 5 | 3 | 2 | — | 8 | 18 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | 3 | 2 | — | 10 | 16 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 1 | 1 | — | 7 | 10 |
| Congenital hyperinsulinism | D044903 | — | — | 1 | 3 | 2 | — | 2 | 8 |
| Hyperinsulinism | D006946 | — | E16.1 | 1 | 4 | 1 | — | 2 | 8 |
| Nesidioblastosis | D046768 | EFO_0007318 | E16.9 | 1 | 3 | 1 | — | 2 | 7 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | 1 | 2 | — | 4 | 7 |
| Neuroblastoma | D009447 | EFO_0000621 | — | — | — | 2 | — | 2 | 4 |
| Lewy body disease | D020961 | EFO_0006792 | G31.83 | 1 | — | 1 | — | 1 | 3 |
| Apathy | D057565 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | — | 3 | 3 | — | — | 6 | 12 |
| Hypoglycemia | D007003 | — | E16.2 | — | 3 | — | — | 2 | 5 |
| Insulinoma | D007340 | — | — | 1 | 1 | — | — | 2 | 4 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | 1 | 2 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 1 | — | — | 1 | 2 |
| Thyroid diseases | D013959 | — | E00-E07 | — | 1 | — | — | 1 | 2 |
| Medullary carcinoma | D018276 | — | — | — | 1 | — | — | 1 | 2 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | 1 | 1 | — | — | — | 2 |
| Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | — | 2 | — | — | — | 2 |
| Cushing syndrome | D003480 | EFO_0003099 | E24 | — | 2 | — | — | — | 2 |
Show 15 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pheochromocytoma | D010673 | — | — | 1 | — | — | — | 3 | 4 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 2 | — | — | — | 2 | 4 |
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | 2 | 3 |
| Multiple system atrophy | D019578 | — | — | 1 | — | — | — | 2 | 3 |
| Dementia | D003704 | EFO_0003862 | F03 | 1 | — | — | — | 2 | 3 |
| Recurrence | D012008 | — | — | 1 | — | — | — | 2 | 3 |
| Gliosarcoma | D018316 | — | — | 1 | — | — | — | 1 | 2 |
| Ependymoma | D004806 | — | — | 1 | — | — | — | 1 | 2 |
| Astrocytoma | D001254 | EFO_0000271 | — | 1 | — | — | — | 1 | 2 |
| Oligodendroglioma | D009837 | EFO_0000631 | — | 1 | — | — | — | 1 | 2 |
Show 7 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Paraganglioma | D010235 | — | — | — | — | — | — | 3 | 3 |
| Papillary thyroid cancer | D000077273 | — | — | — | — | — | — | 3 | 3 |
| Carcinoid tumor | D002276 | — | D3A.00 | — | — | — | — | 2 | 2 |
| Hepatitis c | D006526 | — | B19.2 | — | — | — | — | 2 | 2 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | — | — | 2 | 2 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | — | — | 1 | 1 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | — | — | 1 | 1 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | — | — | — | — | 1 | 1 |
| Nervous system diseases | D009422 | — | G00-G99 | — | — | — | — | 1 | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
Show 23 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Fluorodopa f 18 |
| INN | fluorodopa (18f) |
| Description | 6-((18)F)fluoro-L-dopa is a 6-fluoro-L-dopa and a (18)F radiopharmaceutical. |
| Classification | Small molecule |
| Drug class | dopamine receptor agonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N[C@@H](Cc1cc(O)c(O)cc1[18F])C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 92812-82-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3400972 |
| ChEBI ID | 49166 |
| PubChem CID | 56494 |
| DrugBank | DB13848 |
| UNII ID | 2C598205QX (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,182 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
37 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use